AZD3152 is a long-acting antibody that is used as a prophylactic intervention for the prevention of SARS-Cov-2 infection, and it will be soon available in Finland through a Compassionate Use Program. The aim of this retrospective register study characterize the individuals who have been administered AZD3152 in real-world clinical practice, and to assess the frequency of COVID-19 related events and healthcare resource utilization (HCRU) among these individuals.
